Inducibility of ventricular fibrillation during mild therapeutic hypothermia: electrophysiological study in a swine model

Jaroslav Kudlicka1,2*, Mikulas Mlcek1, Jan Belohlavek3, Pavel Hala1,4, Stanislav Lacko1, David Janak1,5, Stepan Havranek1,3, Jan Malik2, Tomas Janota2, Petr Ostadal4, Petr Neuzil4 and Otomar Kittnar1

Abstract

Introduction: Mild therapeutic hypothermia (MTH) is being used after cardiac arrest for its expected improvement in neurological outcome. Safety of MTH concerning inducibility of malignant arrhythmias has not been satisfactorily demonstrated. This study compares inducibility of ventricular fibrillation (VF) before and after induction of MTH in a whole body swine model and evaluates possible interaction with changing potassium plasma levels.

Methods: The extracorporeal cooling was introduced in fully anesthetized swine (n = 6) to provide MTH. Inducibility of VF was studied by programmed ventricular stimulation three times in each animal under the following: during normothermia (NT), after reaching the core temperature of 32°C (HT) and after another 60 minutes of stable hypothermia (HT60). Inducibility of VF, effective refractory period of the ventricles (ERP), QTc interval and potassium plasma levels were measured.

Results: Starting at normothermia of 38.7 (IQR 38.2; 39.8)°C, HT was achieved within 54 (39; 59) minutes and the core temperature was further maintained constant. Overall, the inducibility of VF was 100% (18/18 attempts) at NT, 83% (15/18) after reaching HT (P = 0.23) and 39% (7/18) at HT60 (P = 0.0001) using the same protocol. Similarly, ERP prolonged from 140 (130; 150) ms at NT to 206 (190; 220) ms when reaching HT (P < 0.001) and remained 206 (193; 220) ms at HT60. QTc interval was inversely proportional to the core temperature and extended from 376 (362; 395) at NT to 570 (545; 599) ms at HT. Potassium plasma level changed spontaneously: decreased during cooling from 4.1 (3.9; 4.8) to 3.7 (3.4; 4.1) mmol/L at HT (P < 0.01), then began to increase and returned to baseline level at HT60 (4.6 (4.4; 5.0) mmol/L, P = NS).

Conclusions: According to our swine model, MTH does not increase the risk of VF induction by ventricular pacing in healthy hearts. Moreover, when combined with normokalemia, MTH exerts an antiarrhythmic effect despite prolonged QTc interval.

Keywords: Mild therapeutic hypothermia, Ventricular fibrillation, Hypokalemia, Long QT interval
**Introduction**

Mild therapeutic hypothermia (MTH) is recommended in patients remaining comatose after cardiac arrest caused by ventricular fibrillation (VF) [1-5] and should be considered in those with other presenting rhythms [6-8]. According to animal studies [9-13], early induction of MTH is supposed to be beneficial, but clinical trials did not prove it consistently yet [14-17]. Consequently, earliest possible induction of MTH is emphasized in some recent protocols using nasopharyngeal evaporative cooling and peripheral veno-arterial extracorporeal membrane oxygenation (ECMO) hoping to improve the neurological outcome [18-22]. On the other hand, the occurrence of malignant ventricular tachyarrhythmias during MTH still remains a major cause of death considering predisposing factors such as myocardial ischemia/reperfusion damage, often reported hypokalemia during the cooling phase [23-25], slowing of the heart rate and QT interval prolongation [25-29].

The aim of this experimental study was to assess the safety of MTH in terms of inducibility of malignant ventricular tachyarrhythmias in relation to spontaneous changes of potassium plasma level and QT interval in a whole body pig model. We hypothesized that MTH related hypokalemia together with prolongation of the QT interval might predispose the heart to greater electrical instability and lower VF threshold.

**Methods**

The experimental protocol was designed to perform electrophysiological (EP) study before and after the induction of MTH using ECMO to provide cooling and hemodynamic support during the stimulation protocol and arrhythmias. All experiments were performed on cross-bred swine (Landrace x White) in an accredited university experimental laboratory by the skilled team of intensive care specialists and laboratory and veterinary technicians. The animals were handled in accordance with the guidelines of research animal use [30]. The protocol was approved by the Charles University First Faculty of Medicine Institutional Animal Care and Use Committee and performed at the Animal Laboratory, Department of Physiology, First Faculty of Medicine, Charles University in Prague in accordance with Act No 246/1992 as amended, Collection of Laws, Czech Republic, that is harmonized with EU Directives 86/609/EEC as amended, 2007/526/ES, 2010/63/EU.

**Anesthesia and monitoring**

After intramuscular sedation and premedication (azaperone 2–3 mg/kg, ketamine 20 mg/kg all i.m.) the marginal ear vein was cannulated and the pigs were preoxygenated with 100% oxygen via a facial mask. General anesthesia was induced by intravenous bolus of propofol (1–2 mg/kg) and orotracheal intubation was performed. Mechanical ventilation was adjusted by Intellivent-ASV closed-loop system (G5, Hamilton Medical, Bonaduz, Switzerland) to maintain normoxia (SpO2 > 97%, pO2 100 mmHg) and normocapnia (EtCO2 38–40 mmHg) respecting the actual metabolic rate. The total intravenous anesthesia was maintained by continuous administration of propofol (6–12 mg/kg/h) and morphine (0.1–0.2 mg/kg/h), pancuronium boluse (4 mg i.v.) were applied when shivering occurred during MTH. The depth of anesthesia was regularly assessed by the photoreaction and the corneal reflex and adjusted accordingly. Intravenous infusion of Ringer’s solution was given to reach and maintain central venous pressure between 6 and 8 mmHg. Anticoagulation was provided by unfractionated heparin bolus (100 IU/kg i.v.) followed by continuous intravenous drip (40–50 IU/kg/h) to maintain target activated clotting time 180–250 seconds (values checked every hour with Hemochron Junior+, International Technidyne Corporation, USA). Sheaths and catheters were inserted to femoral and carotid/jugular vessels as needed. Invasive blood pressure from carotid and pulmonary artery, central venous pressure (TruWave, Edwards Lifesciences, USA), body surface ECG, capnometry and pulse oximetry were continuously monitored by bedside monitor (Life Scope TR, Nihon Kohden, Japan) and trends were recorded. Mixed venous oximetry (SvO2), continuous cardiac output and pulmonary artery temperature were recorded using Swan-Ganz Combo V catheter (Vigilance monitor, Edwards Lifesciences, USA). A diagnostic decapolar catheter (Response CSL, St. Jude Medical, USA) was inserted under fluoroscopic guidance into the apex of the right ventricle (RV) via jugular vein to provide monitoring of intracardiac electrograms and to induce VF. Five bipolar channels were recorded from the apex to base of RV at 3 kHz sampling rate. Heart rate and QT interval were manually measured and QTc was calculated using Bazett’s formula (QTc interval divided by square root of RR interval). Before starting the protocol, cardiopulmonary bypass was established (Figure 1): an inlet 19 F cannula was inserted via femoral vein into the right atrium and an outlet 17 F cannula into abdominal aorta via femoral artery. The cannulae were connected to ECMO circuit consisting of a blood pump (Levitronix Centrimag, Levitronix, USA) and oxygenator (Quadrox, Maquet, Germany). A custom made cooling system was connected to the oxygenator. The cooling system consisted of a rotary pump and reservoir (volume of 15 L) filled with refrigerated water with ice cubes, which were gradually supplemented to keep the temperature of the coolant between 4 and 6°C. The coolant flow rate was set up to approximately 2 L/min during the cooling phase a consequently was slowed as needed to maintain the core temperature of 32°C. The ECMO circuit was primed with 500 mL of normal saline with 2500 IU of unfractionated
The ECMO blood flow was empirically set at 40 mL/kg/min to provide the cooling and to prevent low cardiac output and hypotension during the stimulation protocol. After the onset of VF, the flow was increased to 80–100 mL/kg/min as needed to keep mean arterial pressure of 60 mmHg until an effective pulsatile sinus rhythm with mean arterial pressure above 60 mmHg was restored.

Blood gasses, pH and potassium plasma levels were continuously sampled and recorded in ECMO circuit by a real-time analyzer (CDI 500, Terumo, Japan). At baseline and during the experiment the real-time analyzer was calibrated in 15 minute intervals using a bedside blood analysis system (IRMA TruPoint, International Technidyne Corporation, USA). Despite the expected hypokalemia during MTH, no potassium was replaced during the whole protocol, therefore all changes of potassium plasma levels were spontaneous. Ventilation support, as well as ECMO gas flow, was regularly adjusted to reach the target values (pH 7.4, pO₂ 100 mmHg and pCO₂ 38-40 mmHg).

Electrophysiological study
VF was induced by programmed ventricular stimulation (PVS, Figure 2B). Briefly, electrical stimuli (12 ms duration, maximal stimulation current 20 mA) were delivered from the apex of RV. Eight basic stimuli (S1) of cycle length 350 or 400 ms according to the heart rate were coupled with up to 4 extrastimuli (S2-S5). The coupling interval of S2 was decreased at 10 ms steps until the ventricular effective refractory period (ERP) was achieved. S2 coupling interval was then set to 10 ms above ERP and analogically S3 or S4 stimuli were delivered until VF or absolute ventricular refractory period (ARP) was reached. There were at least 10 s intervals between pacing sequences. VF was defined as an orderless rhythm without detectable QRS complexes lasting longer than 30 s. Normal SR was restituted by the transcutaneous defibrillation using pads placed in the conventional position sternum - apex (TEC-5521, Nihon Kohden, Japan). Biphasic shocks with rising energy (100-150-200-270 J) were delivered as needed. Another PVS procedure was performed at least 10 minutes after SR restoration in a previous one.

Protocol
EP study began at minimum of 60 minutes after connecting ECMO. After the completion of 3 PVS procedures at the baseline (normothermia, NT), the cooling was started and other 3 PVS procedures were performed after reaching the core temperature of 32°C in pulmonary artery (hypothermia, HT). Finally, 3 PVS procedures were carried out after 60 minutes of stable hypothermia (HT60), Figure 2A.

Statistics
Data are presented as median (interquartile range). Each animal was used as its own control and nonparametric pair Friedman test with Dunn’s multiple comparison post test were performed to assess the differences. The linear regression of the dependence of QTc interval on body temperature was performed after passing D’Agostino & Pearson omnibus normality test. The comparison of the VF inducibility was performed by Fisher’s exact test. The P values < 0.05 were considered significant. Statistical analysis and graphs were performed using Prism 5.0 (GraphPad, La Jolla, CA, USA).

Results
Overall, we used 7 animals (female, 4–5 months old, mean weight 51 ± 2 kg). One of them was excluded from analysis because of frequently reoccurring supraventricular
tachyarrhythmias at the baseline. Providing ECMO cooling, the core body temperature dropped from normothermia of 38.7 (38.2; 39.8)°C to 32°C during 54 (39; 59) minutes and was further maintained constant at 31.9 (31.8; 32.0)°C, Figure 3. The potassium plasma level decreased along with the body temperature decline from basal 4.1 (3.9; 4.8) mmol/L to 3.7 (3.4; 4.1) mmol/L (P < 0.01) when reaching HT. In 3 of 6 animals (50%) dropped plasmatic potassium below 3.5 mmol/L, but none of them reached severe hypokalemia (<3.0 mmol/L). Subsequently, during maintaining of HT the potassium plasma level increased spontaneously again and at HT60 was similar to baseline level (4.6 (4.4; 5.0) mmol/L, P = NS, Figure 4A). Heart rate decreased from 148 (123; 161) at baseline to 85 (82; 100) beats per minute at HT (P < 0.001) and remained similar at HT60 (93 (81; 117) beats per minute). The QTc interval was significantly inversely related to the body temperature (−29 ± 2 ms per degree of Celsius, r² = 0.82, Figure 5) and increased from basal 376 (362; 395) ms to 570 (545; 599) ms when reaching HT (P < 0.001) and remained constant at HT60 (206 (193; 220) ms, Figure 4B). Through all the experiments, no spontaneously originating or provoked torsades de pointes (TdP) or heart conduction system disorders were observed. The inducibility of VF at normothermia was 100% (18/18 PVS), 83% (15/18 PVS) when reaching HT, P = NS, and 39% (7/18 PVS) at HT60, P < 0.0001, Table 1, Figure 4C.

Discussion
In our experimental study we have proven that MTH is safe in terms of inducibility of malignant ventricular tachyarrhythmias in healthy pig hearts. Despite our hypothesis, the inducibility of VF was not increased both during the spontaneous transient decline of plasmatic potassium level and concurrent significant prolongation of QTc interval. Moreover, inducibility of VF was even significantly lower after normalization of potassium plasma level. Our data show that the potassium plasma level declines during the cooling phase, while during maintenance of MTH potassium plasma level rises spontaneously and ultimately returns to the baseline value.

Regarding dependence of potassium plasma level on body temperature, our data are concordant to clinical trials by Miryozev et al. [25], Soeholm and Kirkegaard [24]. Nevertheless, none of the animals in our experiment reached severe spontaneous hypokalemia (<3.0 mmol/L) which is supposed to be associated with a higher incidence...
of VT during cooling phase by the clinical trials. The exact mechanism of potassium plasma level changes remains not fully elucidated. In our study we can exclude the possible effects of drugs such as insulin, catecholamines or diuretics, as well as significant ischemic damage of tissues or acid–base changes. Except for the suggested temperature related potassium reversible intra and extra cellular redistribution [31], Polderman et al. [32,33] documented hypothermia-induced polyuria caused by transient tubular dysfunction during the cooling phase which disappeared after maintaining MTH and rewarming. Based on our data, despite hypokalemia as a potential physiological phenomenon, maintaining the normokalemia during MTH contributed to electric stabilization of the myocardium. In accordance with other authors [25,27] we assume that close monitoring of potassium plasma level and its timely supplementation during the cooling phase could help decrease the risk of malignant ventricular arrhythmias.

As observed, the prolongation of QTc interval during MTH had not an adverse effect on arrhythmogenesis of ventricular arrhythmias. The QTc interval was inversely related to the body temperature and was independent of potassium plasma changes. Hypothermia related prolongation of QTc interval and decrease of heart rate were previously described in beagle dogs [34] and also in newborns [35]. According to our data the slope of the curve corresponds to the results in newborns well (-29 ms vs. -21 ms per degree of Celsius). Until recently, the occurrence of the long QT interval during MTH was considered to be a negative prognostic factor in terms of higher incidence of TdP or VF [27,36]. However, recent observational studies and meta-analysis did not prove this assumption [37-40]. Furthermore, as reported by Nishiyama et al. in case reports of congenital long QT syndrome [41], the induction of MTH after cardiac arrest did not have a proarrhythmic effect. Despite prolongation of QTc interval to extreme values during MTH, there were no recurrences of TdP documented. Similarly, in our experiments we have not detected any spontaneous or induced TdP taking into account the limitation in the use of healthy pig hearts.

Decrease in heart rate during MTH might be affected by decreased sympathetic activity as reported by Schwarzl et al. [42], which could also contributed to decreased VF inducibility. According to our previously published data, significant prolongation of ERP was observed as a sign of decreased sympathetic activity after renal denervation [43]. Nevertheless, considering comparable heart rate and ERP at HT and HT60 we can suppose that the tone of autonomic nerve system remained unchanged and could not play a major role in a significant decrease of VF inducibility at HT60.

The influence of profound reduction of myocardial temperature on VF was previously studied in more detail by Chorro et al. [44] in rabbit hearts using high-resolution epicardial mapping and transmural recordings of ventricular activation. They described the antiarrhythmic effect of deep hypothermia (<20°C) by exponential decay of VF dominant frequency, reduction in conduction velocity and subsequently single wave front extinction on activation maps. More recently, Harada et al. [45] proved...
antiarrhythmic effect of MTH in rabbit hearts. Although both MTH and deep hypothermia caused significant prolongation of action potential duration and significant reduction of conduction velocity, the duration of induced ventricular arrhythmias was significantly lower only in MTH. As they observed by high-resolution optical potential mapping, MTH causes a modification of arrhythmia’s spiral wave dynamics (annihilation or exit from the anatomical boundaries) leading to the increase of the chance of arrhythmia self-termination. This corresponds to the results of our study on the pig whole body model.

This study has several translational aspects related to post-resuscitation care. Frequent monitoring and adequate substitution of plasmatic potassium seems to be very important especially during the cooling phase to prevent malignant ventricular arrhythmias. On the other hand, close monitoring of QTc interval and premature termination of MTH due to long QTc appears not to be necessary. There is also potential in treating of incessant ventricular arrhythmias resistant to treatment when MTH could contribute to stabilization of the heart rhythm.

Our study was limited by using healthy animals not considering ischemic-reperfusion injury of the myocardium during the acute myocardial infarction or other predisposition for malignant ventricular arrhythmias. Thus, the translation of the results to humans should be interpreted with caution despite the fact, that our biomodel was represented by a breed repeatedly validated for simulation of human cardiac arrest and resuscitation [46,47]. The number of experimental animals tested is low, however multiple pairwise comparisons in individual animals counterbalances this limitation. The speed of cooling comparing ECMO cardiopulmonary resuscitation protocols [48] was considerably lower. Unlike them, we used a half ECMO flow (40 mL/kg/min) to prevent a hyperkinetic circulation in respect to spontaneous hemodynamics and also the priming the ECMO circuit with the precooled saline could not be applied before. Further, no other ions such as calcium or magnesium have been followed while they might play a significant role. We also did not analyze diuresis and ion excretion in urine. In present study, no potential mapping techniques were used to describe exact mechanisms leading to antiarrhythmic effect of MTH preferring the complexity of the whole body biomodel than open-chest or isolated heart techniques.

**Conclusions**

The induction of MTH in a swine model is safe with respect to the inducibility of malignant ventricular arrhythmias. Potassium plasma level decline during the cooling phase does not impair VF threshold and after achieving spontaneous normokalemia there is a significant effect on the reduction of VF inducibility. Prolongation of QT interval during MTH appears to be a physiological phenomenon reflecting the conduction changes and does not impair the inducibility of VF.

**Key messages**

- MTH does not increase the inducibility of VF in a pig whole body model.
- Despite prolongation of QT interval, prolonged MTH seems to have an antiarrhythmic effect.

**Abbreviations**

- ARP: Absolute refractory period; ECG: Electrocardiogram; ECMO: Extracorporeal membrane oxygenation; EP: Electrophysiological; ERP: Effective refractory period; EtCO$_2$: End-tidal carbon dioxide; HT: Hypothermia of 32°C; HT60: 60 minutes of stable hypothermia 32°C; MTH: Mild therapeutic hypothermia; NT: Normothermia; pCO$_2$: Partial pressure of carbon dioxide; pO$_2$: Partial pressure of oxygen; PVS: Programmed ventricular stimulation; RV: Right ventricle; SpO$_2$: Peripheral capillary oxygen saturation; SvO$_2$: Mixed venous oxygen blood saturation; TdP: Torsades de pointes; VF: Ventricular fibrillation.

**Competing interests**

All authors have no commercial associations that might impose a conflict of interest.

---

### Table 1: Characteristics of ventricular fibrillation induction

| Animal # | NT | Induction parameter (ms) | Inducibility of VF | HT | Induction parameter (ms) | Inducibility of VF | HT60 | Induction parameter (ms) | Inducibility of VF |
|----------|----|-------------------------|-------------------|----|-------------------------|-------------------|------|-------------------------|-------------------|
| 1        | 400/200/140/110/100 | 3/3 | 400/220/130 | 3/3 | 400/270/170/160 (ARP) | 0/3 | | |
| 2        | 350/150/110 | 3/3 | 350/200/170/160 (ARP) | 0/3 | 350/220/140/130 | 3/3 | | |
| 3        | 300/150/90/80 | 3/3 | 350/240/140/130 | 3/3 | 350/230/160/150 (ARP) | 0/3 | | |
| 4        | 350/140/60 | 3/3 | 400/250/180/170 | 3/3 | 400/240/180/170/160 (ARP) | 0/3 | | |
| 5        | 350/150/140 | 3/3 | 350/220/180 | 3/3 | 400/230/220 | 1/3 | | |
| 6        | 300/120/60 | 3/3 | 400/230/160/150 | 3/3 | 400/230/200/190 | 3/3 | | |
| Total    | 100% (18/18) | 83% (15/18) NS | 39% (7/18)*** | | | | | |

Induction parameters represent minimal cycle lengths of basic stimuli and extrastimuli. In each animal and condition was EP protocol made three times. NT indicates normothermia; HT, after reaching the core temperature of 32°C; HT60, after 60 minutes of stable hypothermia. ARP indicates the achievement of absolute refractory period; NS, statistically non-significant; ***P = 0.0001.
Authors’ contributions
JK, MM: made conception and design of the study, performed main procedures of the protocol, data acquisition and statistical analysis, prepared and finalized the manuscript. PH, SL, DJ assisted during the study, cared about ECMO and temperature management. SH participated in a design of EP study and interpretation of EP data. JB, JM, TJ, PO assisted during the study performance and drafted the article. PN and OK participated in a design of the study, contributed to the interpretation of the results, and helped to draft the manuscript. All authors read and approved the final manuscript for publication.

Acknowledgments
This study was supported by research grants of Government of Czech Republic and Charles University in Prague. SVW-2012-264504, PRVOUK-P3B/LF1/10 and NT14160-3/2013.

Authors thank to Alena Ehrlichova, Karel Kypta and Tereza Vavrikova for invaluable technical and lab assistance.

Author details
1Department of Physiology, First Faculty of Medicine, Charles University in Prague, Albertov 8, Prague 2 128 00, Czech Republic.
23rd Department of Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital, U Nemocnice 2, Prague 2 128 00, Czech Republic.
2Department of Cardiology, Na Homolce Hospital, Roentgenova 2/37, Prague 5 150 30, Czech Republic.
2Department of Surgery, Cardiovascular Surgery, First Faculty of Medicine, Charles University in Prague and General University Hospital, U Nemocnice 2, Prague 2 128 00, Czech Republic.

Received: 1 September 2014 Accepted: 5 February 2015

Published online: 22 February 2015

References
1. Hypothermia after Cardiac Arrest Study G. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346:549–56.
2. Bernard SA, Gray TW, Buist MD, Jones BM, Silverstein W, Gutteridge G, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346:557–63.
3. Bellard G, Catte E, Charron C, Caille V, Agearter P, Dubourg O, et al. Efficacy of therapeutic hypothermia after out-of-hospital cardiac arrest due to ventricular fibrillation. Resuscitation. 2007;75:252–9.
4. Castrejon S, Cortes M, Salto ML, Benittez LC, Rubio R, Juarez M, et al. Improved prognosis after using mild hypothermia to treat cardiorespiratory arrest due to a cardiac cause: comparison with a control group. Rev Esp Cardiol. 2009;62:733–41.
5. Peberdy MA, Callaway CW, Neumar RW, Geocadin RG, Zimmerman JL, Donnino M, et al. Part 9: post-cardiac arrest care. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;2010(122):S769–86.
6. Holzer M, Mulliner M, Steer F, Robak O, Kliegel A, Losert H, et al. Efficacy and safety of endovascular cooling after cardiac arrest: cohort study and Bayesian approach. Stroke. 2006;37:1792–7.
7. Arrich J, European Resuscitation Council Hypothermia After Cardiac Arrest Registry Study G. Clinical application of mild therapeutic hypothermia after cardiac arrest. Crit Care Med. 2007;35:1041–7.
8. Deakin CD, Nolan JP, Soar J, Sunde K, Koster RW, Smith GB, et al. European Resuscitation Council Guidelines for Resuscitation 2010 Section 4. Adult advanced life support. Resuscitation. 2010;81:1305–52.
9. Lampe JW, Becker LB. State of the art in therapeutic hypothermia. Annu Rev Med. 2011;62:79–93.
10. Abella BS, Zhao D, Alvarado J, Hamann K, Vandlen Hoek TL, Becker LB. Intra-arrest cooling improves outcomes in a murine cardiac arrest model. Circulation. 2004;109:298–91.
11. Kuboyama K, Safar P, Radosky A, Fisherman SA, Stezoski SW, Alexander H. Delay in cooling negates the beneficial effect of mild resuscitative cerebral hypothermia after cardiac arrest in dogs: a prospective, randomized study. Crit Care Med. 1992;21:1348–58.
12. Takata K, Takeda Y, Sato T, Nakatsuka H, Yokoyama M, Moita K. Effects of hypothermia for a short period on histologic outcome and extracellular glutamate concentration during and after cardiac arrest in rats. Crit Care Med. 2005;33:340–5.
13. Ostadal P, Míček M, Kruger A, Horakova S, Skabradova M, Holy F, et al. Mild therapeutic hypothermia is superior to controlled normothermia for the maintenance of blood pressure and cerebral oxygenation, prevention of organ damage and suppression of oxidative stress after cardiac arrest in a porcine model. J Transl Med. 2013;11:124.
14. Wolff B, Machill K, Schumacher D, Schulzi I, Werner D. Early achievement of mild therapeutic hypothermia and the neurologic outcome after cardiac arrest. Int J Cardiol. 2009;133:223–8.
15. Nielsen N, Hovdenes J, Nilsson F, Roberston S, Stammert P, Sunde K, et al. Outcome, timing and adverse events in therapeutic hypothermia after out-of-hospital cardiac arrest. Acta Anaesthesiol Scand. 2005;53:326–34.
16. Kim F, Nicol G, Maynard C, Hallstrom A, Kudenick PJ, Rea T, et al. Effect of prehospital induction of mild hypothermia on survival and neurological status among adults with cardiac arrest: a randomized clinical trial. JAMA. 2014;311:45–52.
17. Nielsen N, Wetterlev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al. Targeted temperature management at 33 degrees C versus 36 degrees C after cardiac arrest. N Engl J Med. 2013;369:2197–206.
18. Belohlavek J, Kucera K, Jarkovsky J, Franek J, Pokorna M, Danda J, et al. Hyperinvasive approach to out-of-hospital cardiac arrest using mechanical chest compression device, prehospital inaerostat cooling, extracorporeal life support and early invasice assessment compared to standard of care. A randomized parallel groups comparative study proposal. “Prague OHCA study”. J Transl Med. 2012;10:163.
19. Busch HJ, Echwiede F, Fodisch M, Taccoone FS, Wobker G, Schwab T, et al. Safety and feasibility of nasopharyngeal evaporative cooling in the emergency department setting in survivors of cardiac arrest. Resuscitation. 2010;81:943–9.
20. Castren M, Nordberg P, Svensson L, Taccoone F, Vincent JL, Desruelles E, et al. Intra-arrest transternal evaporative cooling: a randomized, prehospital, multicenter study (PRINCE: Pre-ROSC IntraNasal Cooling Effectiveness). Circulation. 2010;122:729–36.
21. Testori C, Holzer M, Steer F, Stratil P, Hartner Z, Moscato F, et al. Rapid induction of mild therapeutic hypothermia by extracorporeal veno-venous blood cooling in humans. Resuscitation. 2013;84:1025–1.
22. Sharma A, Weerwind P, Ganushchak Y, Donker D, Maessen J: Towards a proactive therapy utilizing the modern spectrum of extracorporeal life support: a single-centre experience. Perfusion. 2014. 0267659114530455 (Epub ahead of print).
23. Kohl A, Cane R, Cerullo LJ: Serum potassium levels during prolonged hypothermia. Intensive Care Med. 1992;18:275–7.
24. Szeinhol H, Kirginaard M: Potassium Partage Changes During Therapeutic Hypothermia After Out-of-Hospital Cardiac Arrest—Should It Be Treated? Ther Hypothermia Temperature Manage. 2011;2:30–6.
25. Mirzoyev SA, Leodoud LD, Bunch TJ, Bell MR, White RD: Hypokalemia during the cooling phase of therapeutic hypothermia and its impact on arrhythmogenesis. Resuscitation. 2010;81:1632–6.
26. Lebedzic P, Meiners J, Samol A, Waimer K, Reinecke H, Wanelenberger J, et al. Electrocardiographic changes during therapeutic hypothermia. Resuscitation. 2012;83:602–6.
27. Khan JN, Prasad N, Glancy JM: QTc prolongation during therapeutic hypothermia: are we giving it the attention it deserves? Europace. 2010;12:266–70.
28. Kelly P, Ruskin JN, Vlahajc GJ, Buckley Jr MJ, Freeman CS, Gahan H: Surgical coronary revascularization in survivors of prehospital cardiac arrest: its effect on inducible ventricular arrhythmias and long-term survival. J Am Coll Cardiol. 1990;15:267–73.
29. Reintelt P, Karth GD, Geppert A, Heinz G: Incidence and type of cardiac arrhythmias in critically ill patients: a single center experience in a medical-cardiological ICU. Intensive Care Med. 2001;27:1466–73.
30. McGilone JI, Swanson J: Update on the Guide for the Care and Use of Agricultural Animals in Research and Teaching. J Dairy Sci. 2010;93:12.
31. Sprung J, Cheng EY, Gamulin S, Kampine JP, Bosnjak ZJ: Effects of acute hypothermia and beta-adrenergic receptor blockade on serum potassium concentration in rats. Crit Care Med. 1991;19:1545–51.
32. Podlemin KH: Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009;37:5186–202.
33. Polderman KH, Peerdeman SM, Girbes AR. Hypophosphatemia and hypomagnesemia induced by cooling in patients with severe head injury. J Neurosurg. 2001;94:697–705.

34. van der Linde HJ, Van Deuren B, Teisman A, Towart R, Gallacher DJ. The effect of changes in core body temperature on the QT interval in beagle dogs: a previously ignored phenomenon, with a method for correction. Br J Pharmacol. 2008;154:1474–81.

35. Lasky RE, Parikh NA, Williams AL, Padhye NS, Shankaran S. Changes in the PQRS intervals and heart rate variability associated with rewarming in two newborns undergoing Hypothermia therapy. Neonatology. 2009;96:93–5.

36. Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med. 2002;112:59–66.

37. Tiainen M, Parikka HJ, Makijarvi MA, Takkunen OS, Sarna SJ, Roine RO. Arrhythmias and heart rate variability during and after therapeutic hypothermia for cardiac arrest. Crit Care Med. 2009;37:403–9.

38. Storm C, Hasper D, Nee J, Joerres A, Schefold JC, Kaufmann J, et al. Severe QTc prolongation under mild hypothermia treatment and incidence of arrhythmias after cardiac arrest—a prospective study in 3 survivors with continuous Holter ECG. Resuscitation. 2011;82:859–62.

39. Sykora R, Janda R. [Therapeutic hypothermia after non-traumatic cardiac arrest for 12 hours: Hospital Karlovy vary from 2006 to 2009]. Vnitr Lek. 2011;57:72–7.

40. Riaz A, Hibb H, Foley B, Mulvhill N, Crean P, Murphy RT, et al. Safety of therapeutic hypothermia in post VF/VT cardiac arrest patients. Ir Med J. 2013;106:55–6.

41. Nishiyama N, Sato T, Alzawa Y, Nakagawa S, Kanki H. Extreme QT prolongation during therapeutic hypothermia after cardiac arrest due to long QT syndrome. Am J Emerg Med. 2012;30638: e635-638.

42. Schwartz M, Steendijk P, Huber S, Truschnig-Wilders M, Obermayer-Pietsch B, Maechler H, et al. The induction of mild hypothermia improves systolic function of the resuscitated porcine heart at no further sympathetic activation. Acta physiologica. 2011;203:409–18.

43. Lubanda JC, Kudlicka J, Mlcek M, Chochola M, Neuzl P, Linhart A, et al. Renal denervation decreases effective refractory period but not inducibility of ventricular fibrillation in a healthy porcine biomodel: a case control study. J Transl Med. 2015;13:4.

44. Chorro FJ, Guerrero J, Ferrero A, Tormos A, Mainar L, Millet J, et al. Effects of acute reduction of temperature on ventricular fibrillation activation patterns. Am J Physiol Heart Circ Physiol. 2002;283:H2331–40.

45. Harada M, Honjo H, Yamazaki M, Nakagawa H, Ishiguro YS, Okuno Y, et al. Moderate hypothermia increases the chance of spiral wave collision in favor of self-termination of ventricular tachycardia/fibrillation. Am J Physiol Heart Circ Physiol. 2008;294:H1896–905.

46. Belohlavek J, Mlcek M, Huptych M, Svoboda T, Havranek S, Ost’adal P, et al. Coronary versus carotid blood flow and coronary perfusion pressure in a pig model of prolonged cardiac arrest treated by different modes of venoarterial ECMO and intraaortic balloon counterpulsation. Crit Care. 2012;16:F60.

47. Havranek S, Belohlavek J, Mlcek M, Huptych M, Boucek T, Svoboda T, et al. Median frequencies of prolonged ventricular fibrillation treated by V-A ECMO correspond to a return of spontaneous circulation rate. Int J Artif Organs. 2014;1:48–57.

48. Menegazzi JJ, Salcido DD, Housler GJ, Logue ES. Feasibility of initiating extracorporeal life support during mechanical chest compression CPR: a porcine pilot study. Resuscitation. 2012;83:130–3.